APP:CC - CEO Brad Moore Asked to Deliver Keynote Speech at CannX 2022
(TheNewswire)
Honour follows as the Company announces close of large revenuedeal
Vancouver, British Columbia, Canada - TheNewswire - March 15 - Global Cannabis ApplicationsCorp. (" GCAC" or the" Company" ) ( CSE:APP ) (CNSX:APP.CN) ( FSE:2FA ) ( OTC:FUAPF ), a leading medical cannabis chain-of-custody compliance and dataplatform announces CEO Brad Moore has delivereda virtual keynote speech at CannX 2022 taking place in Tel Aviv,Israel, on March 14-15, 2022.
Medical Cannabis leaders from around the globe will bemeeting in person at the CannX: The 6 th InternationalMedical Cannabis Conference to exchange the latest science, business,and cultivation knowledge. The conference connects “the world’smost influential scientists, clinicians, entrepreneurs, investors,policymakers and thought leaders for the ultimate opportunity to makean impact in the field.” [1]
Brad Moore says, “We are honoured to be invited toshowcase our Efixii platform. With robust compliance and strongersales, it surpasses the outdated seed-to-sale model by improving ourknowledge of the plant, measuring efficacy, and creating superiorconsumer experiences.”
GCAC’s Efixii platform is the first patentedblockchain-based solution for the cannabis industry. It deliverstrusted, certified, regulatory compliant cannabis products thatbenefit all consumers.
Efixii records every step in the cannabis lifecyclefrom the cultivator to the consumer and back. Using theSeedtoSeed TM real-time feedback loop, the continuous flow of informationlets cultivators understand how their product works and improveconsistency. Regulators, law enforcement, manufacturers, retailers,and consumers see trusted data. Scanning an Efixii QR code tells thewhole story, including reviews from other consumers for betterchoices.
AI and deep learning algorithms analyze thousands ofconsumer experiences to measure 'one gram grown, one gram consumed,'and establish efficacy. Medical professionals can prescribe cannabisstrains with improved accuracy, and patients realize the benefits ofthis knowledge. Targeted, high-quality cannabis treatment offersimpressive capabilities.
Brad says, “The seed-to-sale model that has guidedthe industry thus far has critical flaws. The most important is afailure to connect all stakeholders. Simply getting cannabis to themarket fails patients. It’s time to move beyond the outdated modelusing transparent technology to meet compliance, grow sales, establishbaselines, and improve consumer experiences. We showed this ispossible in our most recent announcement where over 10million gramswill be cultivated using Efixii.”[2]
Efixii is licensed to cultivators in a SaaS model andis a free-to-use app for cannabis consumers. All cannabis sold throughthe Portal generates a new sales-commission revenue stream for GCAC.Efixii’s cannabis data is the intellectual property (“IP”) ofGCAC. This IP creates an inherent difficulty in replicating orcompeting with GCAC’s cannabis datasets. GCAC defined theirprotocols in a provisional U.S. patent application, ‘System ofProcess and Tracking Cannabis Products and Associated Method UsingBlockchain’ filed with the USPTO on Dec. 17, 2020.
[1] https://telaviv.cannx.org/
[2]https://newsroom.cannappscorp.com/211847-gcac-signs-definitive-agreement-with-us-1-5m-in-revenue
About Global Cannabis ApplicationsCorp. “GCAC”
GCAC is a global leader in designing, developing, SaaSlicensing and acquiring innovative data technologies for the medicalcannabis industry. The Citizen Green and Efixii platforms are theworld's first end-to-end - from patient to regulator - medicalcannabis data solutions. They use six core technologies: mobileapplications, artificial intelligence, RegTech, smart databases,Ethereum blockchain and GCAC smart rewards. These technologiestransparently disclose cannabis chain-of-custody events, therebyenabling patients to provide crowd-sourced medical cannabis efficacydata. Driven by digital and cannabis industry experts, GCAC is focusedon generating revenue from SaaS licensing its technology and acquiringhigh-quality cannabis datasets that improve patient outcomes andbecome the world’s largest cannabis efficacy data provider.
For more Company information, please visit www.cannappscorp.com , or review itsprofiles on www.sedar.com and on the Canadian Securities Exchange's website www.thecse.com .
PressContact
Phone: +1 (800) 409-5679
Email: info@cannappscorp.com
Forward-Looking Information
This news release mayinclude forward-looking information within the meaning of Canadiansecurities legislation concerning the business of GCAC.Forward-looking information is based on certain key expectations andassumptions made by the management of GCAC. Although management of theCompany believes that the expectations and assumptions on which suchforward-looking information is based are reasonable, undue relianceshould not be placed on the forward-looking information because GCACcan give no assurance that they will prove to be correct.Forward-looking statements contained in this news release are made asof the date of this news release. GCAC disclaims any intent orobligation to update publicly any forward-looking information, whetheras a result of new information, future events or results or otherwise,other than as required by applicable securities laws.
The CanadianSecurities Exchange has not reviewed and does not acceptresponsibility for the adequacy and accuracy of thisinformation.
Copyright (c) 2022 TheNewswire - All rights reserved.